Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolomic Signatures of Brain Atrophy and Ibudilast Response in Progressive Multiple Sclerosis.

medRxiv : the preprint server for health sciences·2026
Same author

Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity.

medRxiv : the preprint server for health sciences·2026
Same author

Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

OMG! A proteomic determinant of neurodegenerative resiliency.

Molecular neurodegeneration·2026
Same author

Serum metabolomic-lipidomic signatures track long-term neurological performance in multiple sclerosis.

Molecular neurodegeneration advances·2025
Same author

Combining inter-eye differences enhances detection of optic nerve involvement in multiple sclerosis.

Brain : a journal of neurology·2025
Same journal

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

1.4K

Metabolomics in multiple sclerosis.

Pavan Bhargava1, Peter A Calabresi2

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|January 13, 2016
PubMed
Summary
This summary is machine-generated.

Metabolomics, the study of small molecules, offers new insights into multiple sclerosis (MS), a central nervous system disorder. This approach may reveal biomarkers and improve precision medicine for MS patients.

Keywords:
Metabolomicsbiomarkersmass spectrometrymultiple sclerosisnuclear magnetic resonance

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.6K
A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

21.9K

Related Experiment Videos

Last Updated: Mar 27, 2026

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

1.4K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.6K
A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

21.9K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Systems Biology

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system disorder with unknown causes, involving inflammation and degeneration.
  • Genetic and environmental factors are implicated in the etiopathogenesis of MS.
  • Existing 'omics' technologies like genomics and proteomics have limitations in capturing disease complexity.

Purpose of the Study:

  • To explore the application of metabolomics in understanding multiple sclerosis.
  • To identify potential biomarkers for MS diagnosis and prognosis.
  • To gain insights into the pathophysiology of MS and advance precision medicine.

Main Methods:

  • Utilizing metabolomics, an 'omics' technology measuring small molecules in biological samples.
  • Employing various analytical platforms for metabolomics data acquisition.
  • Applying both untargeted and targeted metabolomic approaches.
  • Developing and refining data analysis methods for metabolomics.

Main Results:

  • Metabolomics provides information not accessible through genomics, transcriptomics, or proteomics.
  • Ongoing development of analytical and interpretation methods for metabolomics data.
  • Potential for identifying novel biomarkers associated with MS.
  • Opportunity to elucidate disease mechanisms and guide personalized treatment strategies.

Conclusions:

  • Metabolomics holds significant promise for advancing multiple sclerosis research.
  • The technology can contribute to the discovery of diagnostic and prognostic biomarkers.
  • Metabolomics is a valuable tool for understanding MS pathophysiology and enabling precision medicine.